State Board of Administration of Florida Retirement System lifted its holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) by 32.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,852 shares of the biopharmaceutical company’s stock after purchasing an additional 4,110 shares during the quarter. State Board of Administration of Florida Retirement System’s holdings in Sage Therapeutics were worth $1,050,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of SAGE. State of Wisconsin Investment Board acquired a new position in shares of Sage Therapeutics in the second quarter valued at about $1,991,000. Teacher Retirement System of Texas acquired a new stake in Sage Therapeutics during the second quarter worth about $202,000. Schwab Charles Investment Management Inc. grew its stake in Sage Therapeutics by 1.2% during the first quarter. Schwab Charles Investment Management Inc. now owns 131,440 shares of the biopharmaceutical company’s stock worth $9,342,000 after buying an additional 1,593 shares in the last quarter. Rhumbline Advisers grew its stake in Sage Therapeutics by 9.4% during the second quarter. Rhumbline Advisers now owns 41,138 shares of the biopharmaceutical company’s stock worth $3,276,000 after buying an additional 3,551 shares in the last quarter. Finally, Stifel Financial Corp acquired a new stake in Sage Therapeutics during the second quarter worth about $401,000. 95.40% of the stock is currently owned by hedge funds and other institutional investors.
Sage Therapeutics, Inc. (NASDAQ:SAGE) traded down $0.36 during midday trading on Monday, hitting $92.66. The stock had a trading volume of 521,972 shares, compared to its average volume of 549,967. Sage Therapeutics, Inc. has a 12 month low of $44.55 and a 12 month high of $100.50.
Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.98) by $0.01. The firm’s revenue for the quarter was up .0% on a year-over-year basis. research analysts predict that Sage Therapeutics, Inc. will post -7.38 earnings per share for the current fiscal year.
SAGE has been the subject of a number of research reports. BidaskClub cut shares of Sage Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 23rd. Royal Bank Of Canada dropped their price objective on shares of Sage Therapeutics from $145.00 to $137.00 and set an “outperform” rating for the company in a report on Monday, November 27th. J P Morgan Chase & Co dropped their price objective on shares of Sage Therapeutics from $99.00 to $85.00 and set an “overweight” rating for the company in a report on Tuesday, September 12th. Chardan Capital reiterated a “hold” rating on shares of Sage Therapeutics in a report on Wednesday, September 13th. Finally, SunTrust Banks set a $82.00 target price on shares of Sage Therapeutics and gave the company a “buy” rating in a research report on Thursday, October 19th. Three analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Sage Therapeutics presently has a consensus rating of “Buy” and an average price target of $105.14.
ILLEGAL ACTIVITY NOTICE: “State Board of Administration of Florida Retirement System Buys 4,110 Shares of Sage Therapeutics, Inc. (SAGE)” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2017/12/04/state-board-of-administration-of-florida-retirement-system-has-1-05-million-position-in-sage-therapeutics-inc-sage.html.
About Sage Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.